Tritherapies using antiretroviral drugs have proved their worth in industrialized countries in the fight against Aids. However, in Sub-Saharan Africa, where 70 % of people infected with HIV live, access to such treatments is extremely limited. High cost, complicated procedures, combined with inadequate infrastructures for following up patients or capable of delivering medicines regularly partly explain this situation. Moreover, efficacy of antiretroviral agents might not be the same for some HIV strains present in Africa. And not enough is yet known about the response to therapy (viral resistance, adverse effects and so on), notably in patients in advanced stages of immune deficiency. These factors are considered as obstacles to mounting concerted therapy programmes in Africa. For some government authorities they provide the arguments for concentrating control campaigns solely on prevention with no involvement of antiretroviral drugs.
Since 1998 the Senegalese government has been developing a programme facilitating access to Aids treatments (1). Within this, an assessment programme, coordinated by the IRD and the Senegal National Committee for Aids Control, and financed by the Agence nationale de recherches sur le sida (ANRS), has been deployed aiming to determine the effectiveness, the tolerance, the acceptability and feasibility of the standard form of antiretroviral therapy. This study was conducted in a cohort of 58 patients aged between 16 and 56 years, having high viral load and low CD4 cell count. Most of them (86.2%) had developed the disease before the start of the antiretroviral therapy. All received a combination treatment of two nucleoside reverse transcriptase inhibitors plus one protease inhibitor (2) The drugs were taken in three doses per day, just as in the industrialized countries. A sociological survey was done in parallel which assessed patients’ ability to contribute to part of the cost of the treatment depending on their financial resources. The rest would be subsidized by the programme.
At the end of the 18 month study, the results were comparable with those obtained in the countries of the North. Most patients (87.9 %) regularly followed the course of treatment over the whole period monitored. Also, contrary to prior assumptions, financial difficulties did not hinder adherence to the therapy. Furthermore, the same therapeutic efficacy was observed here as in the industrialized countries. After a year and a half of treatment the viral load was almost undetectable (below 500 copies/ml) in 59.3 % of cases and the CD4 cell count had risen markedly (about 180/mm3). Tolerance to antiretroviral medicines was generally good, adverse effects observed being only mild. Only two cases of viral resistance to the drugs were found.
Marie-Lise Sabrie | alfa
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences